Tirzepatide (Mounjaro, Zepbound): A Dual GLP-1/GIP Receptor Agonist for Weight Loss and Diabetes Control In May 2022, tirzepatide was approved for diabetes management under the name Mounjaro, and the FDA expanded this approval to weight loss under the brand name Zepbound in November 2023 (owned by the pharmaceutical company Lilly)
Most users resume or increase exercise intensity during months 4-6 as energy levels normalize and tolerance improves
Michelle Oravitz: I guess well, I used to like the chocolate ones when I was really, really little
The med spa industry is a multi-billion dollar industry, and it is gaining in popularity and trust me, it is the Wild, Wild West, she said
Those who try this approach should pay attention to how their body responds and adjust meal timing if needed
The review also noted that multivitamins, fiber, and probiotics may help address micronutrient gaps and GI side effects common with GLP-1 medications